Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $19.57 Consensus Target Price from Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has received an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $19.5714.

Several research firms have issued reports on ADPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. TD Cowen upped their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Guggenheim reiterated a “buy” rating and set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CFO Kyle Piskel sold 3,115 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total transaction of $40,619.60. Following the completion of the sale, the chief financial officer owned 256,725 shares in the company, valued at approximately $3,347,694. The trade was a 1.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Francis Lo sold 39,741 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09. Following the sale, the insider owned 250,934 shares of the company’s stock, valued at $4,388,835.66. The trade was a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 516,654 shares of company stock worth $7,509,691. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new stake in shares of Adaptive Biotechnologies during the 1st quarter valued at $2,117,000. Bank of America Corp DE increased its position in shares of Adaptive Biotechnologies by 52.3% in the 1st quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock valued at $17,043,000 after buying an additional 421,645 shares in the last quarter. Amundi bought a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at $148,000. California State Teachers Retirement System increased its position in shares of Adaptive Biotechnologies by 28.4% in the 1st quarter. California State Teachers Retirement System now owns 143,658 shares of the company’s stock valued at $1,994,000 after buying an additional 31,782 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at $4,409,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $17.60 on Tuesday. The stock’s fifty day moving average price is $14.57 and its two-hundred day moving average price is $15.68. Adaptive Biotechnologies has a 52-week low of $9.90 and a 52-week high of $20.76. The company has a market cap of $2.82 billion, a price-to-earnings ratio of -53.33 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the business earned ($0.20) EPS. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, equities analysts predict that Adaptive Biotechnologies will post -0.47 EPS for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.